United Therapeutics Corporation

United Therapeutics is a U.S.-based biopharmaceutical company focused on therapies for pulmonary arterial hypertension and other serious rare diseases, along with organ manufacturing technologies. Its commercial portfolio includes inhaled, oral, and injectable medicines, plus delivery devices and related services, sold primarily in the United States with additional international sales for selected products.

49,6 %

87,9 %

41,9 %

+10,6 %

6.60

6.28

— United Therapeutics Corporation
%
Treprostinil-based PAH therapies90% Tyvaso DPI, Nebulized Tyvaso, Remodulin, and Orenitram for pulmonary arterial hypertension and related lung disease.
Oncology7% Unituxin for treatment of high-risk neuroblastoma.
Legacy PAH therapy1% Adcirca tablets sold in the United States for PAH.
Other and services2% Commercial ex vivo lung perfusion services and other revenue items.

The company sells primarily to specialty pharmaceutical distributors and wholesale channels, which then supply patients...

  • U.S. specialty pharmacy distributorsprimary

    Buy treprostinil-based therapies and Orenitram for dispensing to patients; inventory levels and ordering patterns affect shipments.

  • International distributorssecondary

    Buy Nebulized Tyvaso, Remodulin, and Unituxin for resale in approved markets outside the U.S.

  • Hospitals and oncology treatment centerssecondary

    Use Unituxin in high-risk neuroblastoma treatment protocols through oncology distribution channels.

  • Specialist prescribersprimary

    Pulmonary hypertension and lung disease specialists drive adoption of Tyvaso, Remodulin, and Orenitram.

  • Patients with rare diseasesprimary

    End users of the therapies; demand depends on diagnosis, disease progression, and reimbursement access.

United Therapeutics is headquartered in the United States and generates most revenue there, with commercial...

  • •United States is the core commercial market and operating base
  • •Selected products are sold in Europe, Japan, and other international markets
  • •Tyvaso DPI is marketed in the U.S. while other Tyvaso forms have broader reach
  • •Manufacturing and planned capacity are concentrated in North Carolina, Virginia, Minnesota, and Texas
  • •International sales depend on local distributors and regulatory approvals

The company is expanding its commercial franchise in PAH and PH-ILD by growing Tyvaso DPI, Nebulized Tyvaso, and...

01
Expand Tyvaso franchiseshort-term

Tyvaso products are central to the company's commercial base and growth profile.

02
Increase manufacturing capacitymedium-term

Additional facilities are needed to support current demand and future product launches.

03
Advance pipeline and organ technologieslong-term

New indications and organ manufacturing could diversify revenue beyond PAH.

The company is concentrated in treprostinil-based therapies, so any slowdown in Tyvaso, Remodulin, or Orenitram can...

high

Concentration in treprostinil-based products

Tyvaso DPI, Nebulized Tyvaso, Remodulin, and Orenitram make up most revenue.

Scope
Core commercial franchise
Materiality
high
high

Competitive launches in PAH and PH-ILD

New therapies can take share or force price erosion in the core market.

Scope
Tyvaso DPI and related products
Materiality
high
high

Reimbursement and pricing pressure

Net sales depend on payer coverage, rebates, and government pricing actions.

Scope
U.S. commercial products
Materiality
high
high

Patent and generic competition

Loss of exclusivity or challenges to IP can reduce revenue and margins.

Scope
Legacy and core products
Materiality
high
medium

Third-party manufacturing and distribution reliance

Interruptions can delay supply, reduce sales, or impair launches.

Scope
Commercial and clinical operations
Materiality
high
Revenue recognition and gross-to-net deductions
Affects reported revenue and quarterly comparability
Distributor inventory and ordering timing
Creates volatility in reported product sales
Government program accruals
Can change revenue and receivable balances
Stock-based compensation valuation
Affects operating expenses and equity compensation cost

UNITED THERAPEUTICS Corp

UTHR · Pharmaceutical Preparations

Unicycive Therapeutics, Inc.

UNCY · Pharmaceutical Preparations

uniQure N.V.

QURE · Pharmaceutical Preparations

United Health Products, Inc.

UEEC · Orthopedic, Prosthetic & Surgical Appliances & Supplies

Ultragenyx Pharmaceutical Inc.

RARE · Pharmaceutical Preparations

Relay Therapeutics, Inc.

RLAY · Biological Products, (No Diagnostic Substances)

: 29/04/2026